P1253: MAVORIXAFOR DISRUPTS THE CROSS TALK BETWEEN WALDENSTRÖM’S MACROGLOBULINEMIA CELLS AND THE BONE MARROW MICROENVIRONMENT RESULTING IN ENHANCED SENSITIVITY TO B-CELL TARGETED THERAPIES

• H. Monticelli,
• T. Kruitwagen,
• M. Tardelli,
• T. Rebelo,
• B. Maierhofer,
• S. Maier-Munsa,
• K. Zmajkovicova,
• A. G. Taveras,
• C. Nguyen

Affiliations

H. Monticelli

1 X4 Pharmaceuticals (Austria) GmbH, Vienna, Austria

T. Kruitwagen

1 X4 Pharmaceuticals (Austria) GmbH, Vienna, Austria

M. Tardelli

1 X4 Pharmaceuticals (Austria) GmbH, Vienna, Austria

T. Rebelo

1 X4 Pharmaceuticals (Austria) GmbH, Vienna, Austria

B. Maierhofer

1 X4 Pharmaceuticals (Austria) GmbH, Vienna, Austria

S. Maier-Munsa

1 X4 Pharmaceuticals (Austria) GmbH, Vienna, Austria

K. Zmajkovicova

1 X4 Pharmaceuticals (Austria) GmbH, Vienna, Austria

A. G. Taveras

2 X4 Pharmaceuticals, Boston, United States of America

C. Nguyen

1 X4 Pharmaceuticals (Austria) GmbH, Vienna, Austria